David Suzuki

2

Articles

0

Comments
Healthy, full-term Inuit babies are not eligible for palivizumab even though they have four to 10 times the rate of hospital admission compared to “high-risk” infants. (Philippe Put/flickr)

Inuit infants need access to medication to prevent respiratory illness

Anna Banerji, University of Toronto; David Suzuki, University of British Columbia, and Faisal Moola, University of Guelph

A drug called palivizumab can keep babies infected with respiratory syncytial virus (RSV) out of the hospital, but many Inuit babies, who have a higher risk of infection, are not getting it.
How can we make truly informed decisions if the scientific community itself is shut down? AAP Image/Dean Lewins

David Suzuki: Australian scientists should be up on the ramparts

David Suzuki, University of British Columbia

Despite the enormous success of the environmental movement in the 1960s and 70s, we have fundamentally failed to use each of those battles to broaden the public understanding of why we were battling. It…